Idiopathische Interstitielle Pneumonien: Pathomechanismen und Therapieoptionen

P. Markart; L. Hundack; A. Ghofrani; F. Grimminger; W. Seeger; A. Günther

doi:10.1055/s-2005-870955

Pneumologie 2005; 59(8): 554-561
DOI: 10.1055/s-2005-870955

Serie: Auditorium maximum - Pneumologie 2005 (2)

Idiopathische Interstitielle Pneumonien: Pathomechanismen und Therapieoptionen

Idiopathic Interstitial Pneumonias: Pathomechanisms and Therapeutic OptionsP. Markart¹ , L. Hundack¹ , A. Ghofrani¹ , F. Grimminger¹ , W. Seeger¹ , A. Günther¹

¹University of Gießen Lung Center, Gießen

Abstract

Full Text

References

Literatur

1 American Thoracic Society/European Respiratory Society . International multidisciplinary consensus classification of the Idiopathic Interstitial Pneumonias. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med. 2002; 165 277-304
2 Panos R J, Mortenson R, Niccoli S A. et al . Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. Am J Med. 1990; 88 396-404
3 Latsi P I, du Bois R M, Nicholson A G. et al . Fibrotic Idiopathic Interstitial Pneumonia. The prognostic value of longitudinal functional trends. Am J Respir Crit Care Med. 2003; 168 531-537
4 Coultas D B, Zumwalt R E, Black W C. et al . The epidemiology of interstitial lung disease. Am J Respir Crit Care Med. 1994; 150 967-972
5 Schweisfurth H, Kieslich C, Satake N. et al . Wie werden interstitielle Lungenerkrankungen in Deutschland diagnostiziert? Ergebnisse des wissenschaftlichen Registers zur Erforschung von interstitiellen Lungenerkrankungen („Fibroseregister”) der WATL. Pneumologie. 2003; 57 (7) 373-382
6 American Thoracic Society . Idiopathic pulmonary fibrosis: Diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med. 2000; 161 646-664
7 Pardo A, Selman M. Idiopathic pulmonary fibrosis: new insights in its pathogenesis. Int J Biochem Cell Biol. 2002; 34 1534-1538
8 Selman M, King T E, Pardo A. Idiopathic pulmonary fibrosis: Prevaling and evolving hypotheses about its pathogenesis and implications for therapy. Ann Int Med. 2001; 134 136-151
9 Gross T J, Hunninghake G W. Medical progress: Idiopathic pulmonary fibrosis. N Engl J Med. 2001; 345 517-525
10 Uhal B D, Joshi I, Hughes W F. et al . Alveolar epithelial cell death adjacent to underlying myofibriloblasts in advanced fibrotic human lung. Am J Physiol Lung Cell Mol Physiol. 1998; 275 L1192-1199
11 Katzenstein A L. Pathogenesis of “fibrosis” in interstitial pneumonia: an electron microscopic study. Hum Pathol. 1985; 16 1015-1024
12 Wang R, Alam G, Zagariya A. et al . Apoptosis of lung epithelial cells in response to TNF-α requires angiotensin II generation de novo. J Cell Physiol. 2000; 185 253-259
13 Hagimoto N, Kuwano K, Inoshima I. et al . TGF-β1 as an enhancer of Fas-mediated apoptosis of lung epithelial cells. J Immunol. 2002; 168 6470-6478
14 Wang R, Zagariya A, Ang E. et al . Fas-induced apoptosis of alveolar epithelial cells requires ANG II-generation and receptor interaction. Am J Physiol. 1999; 277 L1245-1250
15 Maeyama T, Kuwano K, Kawasaki M. et al . Upregulation of Fas-signalling molecules in lung epithelial cells from patients with idiopathic pulmonary fibrosis. Eur Respir J. 2001; 17 180-189
16 Kuwano K, Kunitake R, Maeyama T. et al . Attenuation of bleomycin-induced pneumopathy in mice by a caspase inhibitor. Am J Physiol Lung Cell Mol Physiol. 2001; 280 L316-325
17 Wang R, Ibarra-Sunga O, Verlinski L. et al . Abrogation of bleomycin-induced epithelial apoptosis and lung fibrosis by captopril or by a caspase inhibitor. Am J Physiol Lung Cell Mol Physiol. 2000; 279 L143-151
18 Selman M, Pardo A. Idiopathic pulmonary fibrosis: an epithelial/fibroblastic cross-talk disorder. Respir Res. 2002; 3 3
19 Kuhn C, McDonald J A. The roles of the myofibroblast in idiopathic pulmonary fibrosis. Ultrastructural and immunohistochemical features of sites of active extracellular matrix synthesis. Am J Pathol. 1991; 138 1257-1265
20 King Jr T E, Schwarz M I, Brown K. et al . Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality. Am J Respir Crit Care Med. 2001; 164 1025-1032
21 Hashimoto N, Jin H, Liu T. et al . Bone marrow-derived progenitor cells in pulmonary fibrosis. J Clin Invest. 2004; 113 243-252
22 Marchand-Adam S, Marchal J, Cohen M. et al . Defect of hepatocyte growth factor secretion by fibroblasts in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2003; 168 1156-1161
23 Kolodsick J E, Peters-Golden M, Larios J. et al . Prostaglandin E₂ inhibits fibroblast to myofibroblast transition via E. Prostanoid receptor 2 signaling and cyclic adenosine monophosphate elevation. Am J Respir Cell Mol Biol. 2003; 29 537-544
24 Clark J G, Kostal K M, Marino B A. Modulation of collagen production following bleomycin-induced pulmonary fibrosis in hamsters. Presence of a factor in lung that increases fibroblast prostaglandin E2 and cAMP and suppresses fibroblast proliferation and collagen production. J Biol Chem. 1982; 257 8098-8105
25 Lama V, Moore B B, Christensen P. et al . Prostaglandin E₂ synthesis and suppression of fibroblast proliferation by alveolar epithelial cells is Cyclooxygenase-2-dependent. Am J Respir Cell Mol Biol. 2002; 27 752-758
26 Selman M, Ruiz V, Cabrera S. et al . TIMP-1, -2, -3, and -4 in idiopathic pulmonary fibrosis. A prevailing nondegradative lung microenvironment?. Am J Physiol Lung Cell Mol Physiol. 2000; 279 L562-574
27 Zuo F, Kaminski N, Eugui E. et al . Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans. Proc Natl Acad Sci USA. 2002; 99 6292-6297
28 MacNee W, Rahman I. Oxidants/antioxidants in idiopathic pulmonary fibrosis. Thorax. 1995; 50 (Suppl 1) S53-58
29 Cantin A M, Hubbard R C, Crystal R G. Glutathione deficiency in the epithelial lining fluid of the lower respiratory tract in idiopathic pulmonary fibrosis. Am Rev Respir Dis. 1989; 139 (2) 370-372
30 Cantin A M, North S L, Fells G A. et al . Oxidant-mediated epithelial cell injury in idiopathic pulmonary fibrosis. J Clin Invest. 1987; 79 (6) 1665-1673
31 Strausz J, Müller-Quernheim J, Steppling H. et al . Oxygen radical production by alveolar inflammatory cells in idiopathic pulmonary fibrosis. Am Rev Respir Dis. 1990; 141(1) 124-128
32 Thannickal V J, Fanburg B L. Activation of an H₂O₂-generating NADH oxidase in human lung fibroblasts by transforming growth factor β₁. J Biol Chem. 1995; 270 30 334-30 338
33 Larios J M, Budhiraja R, Fanburg B L. Oxidative protein cross-linking reactions involving L-tyrosine in transforming growth factor β₁-stimulated fibroblasts. J Biol Chem. 2001; 276 17 437-17 441
34 Geiser Th. Idiopathic pulmonary fibrosis - a disorder of alveolar wound repair?. Swiss Med Wkly. 2003; 133 405-411
35 Lee C G, Homer R J, Zhu Z. et al . Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor β₁. J Exp Med. 2001; 194 809-821
36 Gharaee-Kermani M, McGarry B, Lukacs N. et al . The role of IL-5 in bleomycin-induced pulmonary fibrosis. J Leukoc Biol. 1998; 64 657-666
37 Wallace W A, Ramage E A, Lamb D. et al . A type 2 (Th2-like) pattern of immune response predominates in the pulmonary interstitium of patients with cryptogenic fibrosing alveolitis (CFA). Clin Exp Immunol. 1995; 101 436-441
38 Cambrey A D, Harrison N K, Dawes K E. et al . Increased levels of endothelin-1 in bronchoalveolar lavage fluid from patients with systemic sclerosis contribute to fibroblast mitogenic activity in vitro. Am J Respir Cell Mol Biol. 1994; 11 439-445
39 Peacock A J, Dawes K E, Shock A. et al . Endothelin-1 and endothelin-3 induce chemotaxis and replication of pulmonary artery fibroblasts. Am J Respir Cell Mol Biol. 1992; 7 492-499
40 Shahar I, Fireman E, Topilsky M. et al . Effect of endothelin-1 on α-smooth muscle actin expression and on alveolar fibroblasts proliferation in interstitial lung diseases. Int J Immunopharmacol. 1999; 21 759-775
41 Hocher B, Schwarz A, Fagan K A. et al . Pulmonary fibrosis and chronic lung inflammation in ET-1 transgenic mice. Am J Respir Cell Mol Biol. 2000; 23 19-26
42 Park S H, Saleh D, Giaid A. et al . Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist. Am J Respir Crit Care Med. 1997; 156 (2 Pt 1) 600-608
43 Mutsaers S E, Marshall R P, Goldsack N R. et al . Effect of endothelin receptor antagonists (BQ-485, Ro 47 - 0203) on collagen deposition during the development of bleomycin-induced pulmonary fibrosis in rats. Pulm Pharmacol Ther. 1998; 11 221-225
44 Uguccioni M, Pulsatelli L, Grigolo B. et al . Endothelin-1 in idiopathic pulmonary fibrosis. J Clin Pathol. 1995; 48 330-334
45 Giaid A, Michel R P, Stewart D J. et al . Expression of endothelin-1 in lungs of patients with cryptogenic fibrosing alveolitis. Lancet. 1993; 341 1550-1554
46 Border W A, Noble N A. Mechanisms of Disease: Transforming Growth Factor (β) in Tissue Fibrosis. N Engl J Med. 1994; 331 (19) 1286-1292
47 Coker R K, Laurent G J. Pulmonary fibrosis: cytokines in the balance. Eur Respir J. 1998; 11 1218-1221
48 Sime P J, Xing Z, Graham F L. et al . Adenoviral-mediated gene transfer of active TGF-β₁ induces prolonged aggressive fibrosis in rat lung. J Clin Invest. 1997; 100 768-776
49 Giri S N, Hyde D M, Hollinger M A. Effect of antibody to transforming growth factor β on bleomycin induced accumulation of lung collagen in mice. Thorax. 1993; 48 959-966
50 Wang Q, Wang Y, Hyde D M. et al . Reduction of bleomycin induced lung fibrosis by transforming growth factor β soluble receptor in hamsters. Thorax. 1999; 54 805-812
51 Broekelmann T J, Limper A H, Colby T V. et al . Transforming growth factor β₁ is present at sites of extracellular matrix expression in human pulmonary fibrosis. Proc Natl Acad Sci. 1991; 88 6642-6646
52 Nogee L M, Dunbar 3rd A E, Wert S E. et al . A mutation in the surfactant protein C gene associated with familial interstitial lung disease. N Engl J Med. 2001; 344 573-579
53 Mulugeta S, Nguyen V, Russo S J. et al . A Surfactant Protein C Precursor Protein BRICHOS Domain Mutation Causes Endoplasmic Reticulum Stress, Proteasome Dysfunction, and Caspase 3 Activation. Am J Respir Cell Mol Biol. 2005; 32 521-530
54 Glasser S W, Detmer E A, Ikegami M. et al . Pneumonitis and emphysema in sp-C gene targeted mice. J Biol Chem. 2003; 278 14 291-14 298
55 Shulenin S, Nogee L M, Annilo T. et al . ABCA 3-gene mutations in newborns with fatal surfactant deficiency. N Engl J Med. 2004; 350 1296-1303
56 Nakatani Y, Nakamura N, Sano J. et al . Interstitial pneumonia in Hermansky-Pudlak syndrome: significance of florid foamy swelling/degeneration (giant lamellar body degeneration) of type-2 pneumocytes. Virchows Arch. 2000; 437 304-313
57 Padmavathy B, Devaraj H, Devaraj N. Amiodarone-induced changes in surfactant phospholipids of rat lung. Naunyn Schmiedebergs Arch Pharmacol. 1993; 347 421-424
58 Kotani I, Sato A, Hayakawa H. et al . Increased procoagulant and antifibrinolytic activities in the lungs with idiopathic pulmonary fibrosis. Thromb Res. 1995; 77 493-504
59 Gunther A, Mosavi P, Ruppert C. et al . Enhanced tissue factor pathway activity and fibrin turnover in the alveolar compartment of patients with interstitial lung disease. Thromb Haemost. 2000; 83 853-860
60 Burkhardt A. Alveolitis and collapse in the pathogenesis of pulmonary fibrosis. Am Rev Respir Dis. 1989; 140 (2) 513-524
61 McDonald J A. The yin and yang of fibrin in the airways. N Engl J Med. 1990; 322 929-931
62 Chambers R C, Dabbagh K, McAnulty R J. et al . Thrombin stimulates fibroblast procollagen production via proteolytic activation of protease-activated receptor 1. Biochem J. 1998; 333 121-127
63 Menshikov M, Elizarova E, Plakida K. et al . Urokinase upregulates matrix metalloproteinase-9 expression in THP-1 monocytes via gene transcription and protein synthesis. Biochem J. 2002; 367 833-839
64 Carmeliet P, Moons L, Lijnen R. et al . Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat Genet. 1997; 17 439-444
65 Eitzman D T, McCoy R D, Zheng X. et al . Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest. 1996; 97 232-237
66 Gunther A, Lubke N, Ermert M. et al . Prevention of bleomycin-induced lung fibrosis by aerosolization of heparin or urokinase in rabbits. Am J Respir Crit Care Med. 2003; 168 1358-1365
67 Sisson T H, Hanson K E, Subbotina N. et al . Inducible lung-specific urokinase expression reduces fibrosis and mortality after lung injury in mice. Am J Physiol Lung Cell Mol Physiol. 2002; 283 L1023-1032
68 Behr J, Maier K, Degenkolb B. et al . Antioxidative and clinical effects of high-dose N-Acetylcysteine in fibrosing alveolitis. Adjunctive therapy to maintenance immunosuppression. Am J Respir Crit Care Med. 1997; 156 1897-1901
69 Behr J, Degenkolb B, Krombach F. et al . Intracellular glutathione and bronchoalveolar cells in fibrosing alveolitis: effects of N-acetylcysteine. Eur Respir J. 2002; 19 906-911
70 Behr J, Demedts M, Buhl R. et al . IFIGENIA (idiopathic pulmonary fibrosis international group exploring NAC I annual): effects of N-acetylcysteine (NAC) on lung function and gas exchange in IPF patients. Eur Respir J. 2004; 24 (Suppl 48) 668S
71 Ziesche R, Hofbauer E, Wittmann K. et al . A preliminary study of long-term treatment with interferon γ-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 1999; 341 1264-1269
72 Raghu G, Brown K K, Bradford W Z. et al . Idiopathic Pulmonary Fibrosis Study Group. A p-controlled trial of interferon γ-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2004; 350 125-133
73 Margolin S B, Lefkowitz S. Pirfenidone: a novel pharmacologic agent for prevention and resolution of lung fibrosis. FASEB J. 1994; 8 A382
74 Iyer S N, Gurujeyalakshmi G, Giri S N. Effects of pirfenidone on transforming growth factor-β gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther. 1999; 291 367-373
75 Raghu G, Johnson W C, Lockhart D. et al . Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II-study. Am J Respir Crit Care Med. 1999; 159 1061-1069
76 Azuma A, Nukiwa T, Tsuboi E. et al . Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2005; 171 1040-1047
77 Guenther A, Enke B, Markart P. et al . Safety and Tolerability of an Oral Dual Endothelin Receptor Antagonist (Bosentan) in Patients with Idiopathic Pulmonary Fibrosis - An Open-Label-Study. Am J Respir Crit Care Med. 2005; 171 A120 (Abstract)
78 Nakayama K, Kubo H, Yanai M. et al . Anticoagulant Therapie for Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2005; 171 A18 (Abstract)
79 Thannickal V J, Toews G B, White E S. et al . Mechanisms of Pulmonary Fibrosis. Annu Rev Med. 2004; 55 395-417

P. Markart

University of Giessen Lung Center

Klinikstraße 36

35392 Gießen ·

Email: Philipp.Markart@innere.med.uni-giessen.de